KW 6356Alternative Names: KW-6356
Latest Information Update: 25 Mar 2017
At a glance
- Originator Kyowa Hakko Kirin
- Class Antiparkinsonians
- Mechanism of Action Adenosine A2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 01 Sep 2016 Phase-II clinical trials in Parkinson's disease in Japan (PO) (JapicCTI163395)